Trial Profile
A prospective, observational study investigating safety and efficacy of ombitasvir/paritaprevir/ritonavir plus ribavirin in patients with chronic Hepatitis C genotype 4 infection: a real life study in Saudi Arabia
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2017
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 06 Feb 2017 New trial record